title: Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
authors: Sara
authors: S
authors: Ali
authors: Ruhena
authors: R
authors: Sergeant
authors: Stephen G
authors: SG
authors: O'Brien
authors: Letizia
authors: L
authors: Foroni
authors: Corinne
authors: C
authors: Hedgley
authors: Gareth
authors: G
authors: Gerrard
authors: Dragana
authors: D
authors: Milojkovic
authors: Kate
authors: K
authors: Stringaris
authors: Ahmad
authors: A
authors: Khoder
authors: Abdullah
authors: A
authors: Alsuliman
authors: Maria
authors: M
authors: Gilleece
authors: Ian H
authors: IH
authors: Gabriel
authors: Nichola
authors: N
authors: Cooper
authors: John M
authors: JM
authors: Goldman
authors: Jane F
authors: JF
authors: Apperley
authors: Richard E
authors: RE
authors: Clark
authors: David
authors: D
authors: Marin
authors: Katayoun
authors: K
authors: Rezvani
mesh_terms: D000069439:Dasatinib; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D054340:Receptors, KIR / Q000235:genetics* / Q000378:metabolism; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: C496212:KIR2DS1 protein, human; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D054340:Receptors, KIR; D013844:Thiazoles; D000069439:Dasatinib